{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016726","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2026-05-13T20:12:25+00:00","discovered_at":"2026-05-13T20:13:00.301771+00:00","generated_at":"2026-05-13T22:00:35.341061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M","bullets":["Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.","Net loss $3.5M ($0.90/share) vs $3.8M ($4.38/share) a year ago.","Cash $9.3M at March 31, down from $12.0M at Dec 31, 2025.","NEUTRALIZE-AKI trial enrolled 198 of 339 patients; PMA submission efforts initiated.","Added 7 children’s hospitals, now 17 total, targeting 15 more in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016726","json":"https://secwatch.observer/filing/0001437749-26-016726.json","markdown":"https://secwatch.observer/filing/0001437749-26-016726.md","text":"https://secwatch.observer/filing/0001437749-26-016726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926016726/0001437749-26-016726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926016726/icu20260408_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T22:00:35.341061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}